Silexion Therapeutics Corp. has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. SIL-204 is a next-generation siRNA candidate designed to target a broad range of ...
Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...
Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...
Gift 5 articles to anyone you choose each month when you subscribe. Biotech company Alterity Therapeutics is seeking to raise about $40 million following stellar results from a Phase 2 results ...
Viking Therapeutics showcased significant clinical progress across its pipeline in 2024, with VK2735 emerging as a key driver for future growth. The company is well-positioned for Phase 3 trials ...
United Therapeutics said Monday that the Food and Drug Administration has cleared it to begin the first clinical trial testing whether organs from gene-edited pigs could provide a viable option ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
On Wednesday, oncology research firm Cargo Therapeutics said in a news release that it was halting a clinical trial because of poor results. The company’s 51 lymphoma patients gave some ...
This is where RNA-based therapies are poised to make a significant impact. RNA-based precision therapeutics are emerging as a game-changer for genetic disorders, including IRDs. Unlike DNA or ...
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Thursday. The Dow traded up 0.26% to 44,829.59 while the NASDAQ gained 0.75% to 19,779.27. The S&P 500 ...
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results